梯瓦制药 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) +972(3)914-8213(Registrant’s telephone number, including area code) Title of each classAmerican Depositary Shares, each representingone Ordinary Share Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulationS-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-acceleratedfiler, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule12b-2of the Exchange Act. Large accelerated filer☒Non-acceleratedfiler☐Emerginggrowthcompany☐ Acceleratedfiler Smallerreportingcompany If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2of the Act).Yes☐No☒ As of June30, 2025, the registrant had1,147,150,917ordinary shares outstanding. Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED For an accessible version of this Quarterly Report onForm10-Q,please visit www.tevapharm.com INDEX PART I.Financial Statements (unaudited) Item 1.Financial Statements (unaudited)Consolidated Balance SheetsConsolidated Statements of Income (loss)Consolidated Statements of Comprehensive Income (loss)Consolidated statements of changes in equityConsolidated Statements of Cash FlowsNotes to Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures about Market RiskItem 4.Controls and Procedures PARTII.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED INTRODUCTION AND USE OF CERTAIN TERMS Unless otherwise indicated, all references to the “Company,” “we,” “our” and “Teva” refer to Teva Pharmaceutical Industries Limited and itssubsidiaries, and references to “revenues” refer to net revenues. References to “U.S. dollars,” “dollars,” “U.S. $” and “$” are to the lawful currency ofthe United States of America, and references to “NIS” are to new Israeli shekels. References to “ADS(s)” are to Teva’s American Depositary Share(s).References to “MS” are to multiple sclerosis. Market data, including both sales and share data, is based on information provided by IQVIA, a providerof market research to the pharmaceutical industry (“IQVIA”), unless otherwise stated. References to “R&D” are to Research and Development,references to “IPR&D” are toin-processR&D, references to “S&M” are to Selling and Marketing and references to “G&A” are to General andAdministrative. Some amounts in this report may not add up due to rounding. All percentages have been calculated using unrounded amounts. Thisreport on Form10-Qcontains many of the trademarks and trade names used by Teva in the United States and internationally to distinguish its productsand services. Any third-party trademarks mentioned in this report are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS In addition to historical information, this Quarterly Report on Form10-Q,and the reports and documents incorporated by reference in thisQuarterly Report on Form10-Q,may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, thatcould cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.These forward-looking statements include statements concerningour plans, strategies, objectives, future performance and financial and operatingtargets, and any other information tha